Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esketamine - Solvonis Therapeutics

Next Previous
Drug Profile

Esketamine - Solvonis Therapeutics

Alternative Names: AWKN-002; S-ketamine-Solvonis Therapeutics; SVN-002-Solvonis Therapeutics

Latest Information Update: 09 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lohmann Therapie-Systeme
  • Class Amines; Analgesics; Antidepressants; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; Cyclohexanones; Ear disorder therapies; General anaesthetics; Ketones; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Alcoholism

Most Recent Events

  • 09 Jun 2026 Solvonis Therapeutics plans a phase IIb trial for Alcoholism (Solvonis Therapeutics, June 2026)
  • 27 May 2025 Solvonis Therapeutics has patent protection for Esketamine oral thin film (OTF) formulation
  • 09 Apr 2024 Esketamine - Awakn Life Sciences is available for licensing as of 09 Apr 2024. https://awaknlifesciences.com/licensing-partnerships

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top